Antiphospholipid Antibodies and Stroke Study "APASS"


Phase N/A Results


720 patients (41%) were determined to be aPL positive, and 1050 patients were classified as being aPL negative (59%). The two-year composite event rate was 22.2% among the aPL positive group, and 21.8% in the aPL negative group. There were no statistically significant differences in outcome associated with a baseline aPL status among patients treated with either warfarin or aspirin.